IGFBP1 and neoplasm: It is possible that this dual activity could also explain the inconsistent results from previous studies looking at the clinical value of IGFBP-1 and IGFBP-2, as well as their tumor- or stage-dependent prognostic effect [30,31,32,33,34,35,36,37,38,39].